Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft-versus-host disease
✍ Scribed by Sanders, Jean E. ;Flournoy, Nancy ;Thomas, E. Donnall ;Buckner, C. Dean ;Lum, Lawrence G. ;Clift, Reginald A. ;Appelbaum, Frederick R. ;Sullivan, Keith M. ;Stewart, Patricia ;Deeg, H. Joachim ;Doney, Kristine ;Storb, Rainer
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 791 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
One hundred fourteen children with acute lymphoblastic leukemia were treated with allogeneic marrow transplantation from HLAidentical siblings after conditioning with cyclophosphamide and total body irradiation. Methotrexate was given posttransplantation for prophylaxis of graft-versus-host disease. The minimum follow-up after transplantation was 2 years. Sixteen of 51 patients transplanted in marrow remission survive from 2.1 to 8.9 years (median 2.3, 13 in continuous remission, one in remission following testicular relapse, and two after marrow relapse. Sixty-three were transplanted in relapse and eight survived 3-10 years (median 5.3, five in continuous remission, and three in remission following testicular relapse. In a multivariate analysis, factors significantly related to increased survival were marrow remission at transplant (p < 0.007) and chronic graft-versus-host disease (p < 0.005). Factors associated with increased relapse were marrow relapse at transplant (p < 0.002) and absence of significant graft-versus-host disease (p < 0.004). The development of acute graft-versushost disease was associated with high marrow cell doses (p < 0.04). These data suggest that some children with acute lymphoblastic leukemia and a poor prognosis with conventional chemotherapy may be cured with marrow transplantation.